论文部分内容阅读
目的探讨奥拉西坦联合依达拉奉对急性脑梗死的保护作用。方法 88例急性脑梗死患者分为治疗组和对照组,均给予阿托伐他仃、阿司匹林,奥拉西坦治疗。治疗组在此基础上加用依达拉奉。于治疗前及治疗后第1、3、7、14天,分别进行临床神经功能缺损评分和疗效评定。结果治疗组总有效率90.7%,明显高于对照组的59.1%(P<0.05)。生活能力评定治疗组独立及轻度依赖率72.7%,明显高于对照组的40.9%(P<0.05)。两组均无明显不良反应。结论奥拉西坦联合依达拉奉治疗脑梗死,安全有效。
Objective To investigate the protective effect of oxiracetam combined with edaravone on acute cerebral infarction. Methods 88 patients with acute cerebral infarction were divided into treatment group and control group, were given atorvastatin, aspirin, oxiracetam treatment. The treatment group added edaravone on the basis of this. Before treatment and on the 1st, 3rd, 7th and 14th days after treatment, clinical neurological deficit score and curative effect were evaluated respectively. Results The total effective rate was 90.7% in the treatment group, which was significantly higher than that in the control group (59.1%, P <0.05). The independent and mild dependence rate of the assessment of viability in the treatment group was 72.7%, which was significantly higher than that in the control group (40.9%, P <0.05). No significant adverse reactions in both groups. Conclusions Oxiracetam combined with edaravone is safe and effective in the treatment of cerebral infarction.